Bradykinin: The Vasoactive Nonapeptide in Kallikrein-Kinin System, Inflammation, and Pain Research (2026)

# Bradykinin: The Vasoactive Nonapeptide in Kallikrein-Kinin System, Inflammation, and Pain Research (2026)

Bradykinin is one of the most extensively studied vasoactive peptides in biomedical research. As the primary effector molecule of the kallikrein-kinin system (KKS), this 9-amino-acid peptide participates in cardiovascular regulation, inflammatory signaling, pain transduction, and renal physiology. Its intersection with the renin-angiotensin-aldosterone system (RAAS), the coagulation cascade, and the COVID-19 pathophysiology debate has elevated bradykinin to a central position in translational research.

This profile covers bradykinin''s structure, biosynthesis, receptor biology, physiological functions, and its roles in hereditary angioedema (HAE), COVID-19-related vascular pathology, and pain research — with a focus on research-grade compounds and their laboratory applications.

> Research Use Only (RUO): Bradykinin and related kinin peptides described in this article are for in vitro research and laboratory investigation only. They are not approved for human or veterinary therapeutic use.

---

What Is Bradykinin?

Bradykinin (BK) is an endogenous nonapeptide — a 9-amino-acid chain — belonging to the kinin family of vasoactive peptides. It is rapidly generated from large precursor proteins called kininogens through the action of kallikrein enzymes. First described by Rocha e Silva and colleagues in 1949 through experiments involving trypsin digestion of plasma proteins, bradykinin has since become a cornerstone molecule in vascular biology, pain research, and inflammatory pharmacology.

The name "bradykinin" derives from the Greek bradys (slow) and kinein (to move), reflecting its original characterization as a slowly acting contractile substance in intestinal smooth muscle — distinguishing it from the rapidly acting histamine. Despite this designation, modern research reveals bradykinin as a pleiotropic peptide with effects spanning seconds to minutes depending on tissue context and receptor expression.

Bradykinin is part of a broader kinin family that includes:

• •Bradykinin (nonapeptide): Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
• •Kallidin (Lys-bradykinin, decapeptide): Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
• •Des-Arg⁹-bradykinin (octapeptide, B1 receptor agonist): Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe
• •Des-Arg¹⁰-kallidin (B1 receptor agonist)

---

Structure and Biosynthesis

Amino Acid Sequence and Molecular Properties

Bradykinin has the sequence RPPGFSPFR (single-letter code). Its molecular formula is C₅₀H₇₃N₁₅O₁₁, with a molecular weight of approximately 1,060 Da. The peptide exists as a linear nonapeptide under physiological conditions, though its conformation when receptor-bound is critically shaped by the proline-rich core that imposes structural rigidity.

Key molecular features include:

• •N-terminal Arg¹: Essential for B2 receptor recognition; its removal abolishes B2R activity
• •C-terminal Arg⁹: Required for B2 receptor binding; its removal by carboxypeptidase N generates des-Arg⁹-BK (the B1R agonist)
• •Pro²-Pro³ motif: Structural rigidity through imino acid geometry constrains the peptide backbone
• •Phe⁵ and Phe⁸: Aromatic residues that mediate hydrophobic receptor interactions critical for potency

The plasma half-life of bradykinin is extremely short — approximately 15–30 seconds — owing to rapid degradation by angiotensin-converting enzyme (ACE), kininase I (carboxypeptidase N and M), neutral endopeptidase/neprilysin (NEP, CD10), and aminopeptidase P. This rapid inactivation means bradykinin acts predominantly as a local autocrine/paracrine signal rather than a circulating hormone.

The Kallikrein-Kinin System (KKS)

Bradykinin is generated through a proteolytic cascade:

1. Kininogens — the precursor proteins:

• •High-molecular-weight kininogen (HK/HMWK): Approximately 110 kDa; circulates in plasma; co-factor for contact activation
• •Low-molecular-weight kininogen (LK/LMWK): Approximately 68 kDa; present in plasma and tissues

2. Kallikrein enzymes cleave kininogens:

• •Plasma kallikrein (KLKB1) acts on HK → liberates bradykinin (9-mer)
• •Tissue kallikrein (KLK1) acts on both HK and LK → liberates kallidin (10-mer)

3. Receptor activation: Released kinins act at B1R (des-Arg metabolites) and B2R (intact bradykinin/kallidin) on target tissues.

Activation of plasma kallikrein is triggered by activated factor XII (FXIIa) — a serine protease at the nexus of the contact activation system. FXIIa activates prekallikrein (the zymogen form), which then cleaves HK to generate bradykinin. This connection links the kinin system to the intrinsic coagulation pathway, explaining why conditions that activate the contact system (sepsis, HAE, artificial surface contact) generate bradykinin and drive inflammatory vascular changes.

The KKS-RAAS Interface

The KKS is intimately integrated with the renin-angiotensin-aldosterone system (RAAS):

• •ACE (Angiotensin-Converting Enzyme): Converts angiotensin I → vasoconstrictor angiotensin II AND degrades bradykinin (bradykinin is an ACE substrate via its C-terminal dipeptide cleavage)
• •ACE2: Converts Ang II → vasodilatory angiotensin 1-7 AND also degrades des-Arg⁹-bradykinin (the B1R agonist)
• •Angiotensin 1-7 (covered in depth in our Angiotensin-(1-7) research profile) acts through the Mas receptor to oppose ACE/angiotensin II effects, partly complementing bradykinin''s vasodilatory actions

This dual role of ACE explains a classic pharmacological observation: ACE inhibitors (captopril, enalapril) reduce blood pressure not only by blocking angiotensin II production but also by preventing bradykinin degradation. Accumulated bradykinin drives additional vasodilation — beneficial for blood pressure and cardiovascular outcomes — but also causes the characteristic dry cough (tracheal bradykinin-mediated sensitization) and, rarely, life-threatening angioedema (massive bradykinin-driven vascular permeability increase).

---

Bradykinin Receptor Biology

Bradykinin exerts its biological effects through two G protein-coupled receptors: the constitutive B2 receptor and the inducible B1 receptor. These receptors have distinct expression patterns, agonist preferences, and signaling characteristics that explain the different temporal phases of kinin-mediated responses.

B2 Receptor (BDKRB2)

The B2 receptor is constitutively expressed in most cell types under baseline conditions, including vascular endothelium, vascular smooth muscle, sensory neurons, fibroblasts, bronchial epithelium, and CNS cells. It is the principal receptor for intact bradykinin (RPPGFSPFR) and kallidin.

Signaling pathways activated by B2R:

A critical feature of B2R is rapid homologous desensitization and internalization following agonist binding — making it primarily relevant to acute signaling. The 2021 cryo-EM structure of human B2R bound to peptide agonist and Gq (published in Nature Structural & Molecular Biology, DOI: 10.1038/s41594-021-00645-y) has resolved the molecular basis for kinin recognition and receptor activation at atomic resolution, enabling rational design of new modulators.

B1 Receptor (BDKRB1)

The B1 receptor is minimally expressed under basal conditions but undergoes dramatic transcriptional upregulation during tissue injury, infection, or chronic inflammation. Its primary endogenous agonists are des-Arg⁹-bradykinin (the C-terminal-truncated metabolite of bradykinin) and des-Arg¹⁰-kallidin.

B1R upregulation is driven by:

• •Pro-inflammatory cytokines: IL-1β, TNF-α, IL-6
• •Bacterial lipopolysaccharide (LPS)
• •NFκB-mediated transcriptional induction
• •Tissue injury and hypoxia

Unlike B2R, B1R does not undergo rapid desensitization, making it a sustained signaling mechanism ideally suited for maintaining chronic inflammatory tone. This desensitization asymmetry between B1R and B2R creates a temporal shift in kinin signaling: B2R mediates the acute phase and B1R sustains the chronic phase of inflammatory and nociceptive responses.

A 2024 study in PAIN (PMC: 10081334) demonstrated that human dorsal root ganglia neurons express both B1R and B2R, with distinct intracellular calcium kinetics and sensitization patterns — providing direct cellular evidence for the B2R (acute) and B1R (chronic) pain signaling model.

---

Physiological and Pathophysiological Actions

Cardiovascular Effects

Bradykinin is a potent vasodilator with effects on vascular tone, endothelial function, and cardiac protection. Key cardiovascular research areas include:

Endothelium-Dependent Vasodilation:

B2R activation on endothelial cells triggers eNOS activation → NO production → diffusion to vascular smooth muscle → cGMP-mediated relaxation. This endothelium-dependent vasodilation is a major component of the protective cardiovascular effects attributed to ACE inhibition.

Cardioprotection in Ischemia:

Experimental evidence from isolated heart and in vivo models supports bradykinin in ischemic preconditioning — a phenomenon where brief ischemic episodes protect against subsequent prolonged ischemia. Bradykinin-mediated cardioprotection involves NO, PGI₂, PKC, and mitochondrial KATP channel opening. This pathway partially explains why ACE inhibitors reduce cardiovascular mortality beyond simple blood pressure reduction.

Vascular Permeability:

Bradykinin is one of the most potent inducers of increased vascular permeability in the body, acting on endothelial cells to disrupt tight junctions via Rho kinase-mediated actomyosin contraction. This effect is central to edema formation at inflammation sites and is the pharmacological basis for bradykinin''s role in angioedema.

Natriuresis:

Tissue kallikrein-kinin activity in the kidney tubule contributes to natriuresis and diuresis by opposing aldosterone-driven sodium retention — making the renal KKS an important counterregulatory system to the RAAS.

Pain and Nociception

Bradykinin is among the most potent endogenous algogenic agents — able to produce sharp or burning pain at nanomolar concentrations when injected into tissue. Its molecular nociceptive mechanism involves a multi-step sensitization cascade:

1. B2R activation on C-fiber nociceptors → Gq → PLC → IP₃-mediated intracellular Ca²⁺ rise

2. Inhibition of M-type potassium channels → increased neuronal excitability and action potential firing

3. Opening of calcium-activated chloride channels → membrane depolarization

4. PKC-mediated phosphorylation of TRPV1 (the capsaicin receptor) → heat hypersensitivity and hyperalgesia

5. Sensitization of TRPA1 → mechanical and chemical hypersensitivity

6. PLA₂ → COX → PGE₂ generation → further lowering of nociceptor threshold

This cascade places bradykinin at the intersection of acute tissue-injury signaling and inflammatory pain sensitization. The neuropeptide network at inflammatory sites involves not only bradykinin but also Substance P and the tachykinin family, CGRP (Calcitonin Gene-Related Peptide), and endogenous opioids like beta-endorphin that together determine the net nociceptive tone.

Despite clear preclinical pain pharmacology, clinical translation of kinin receptor antagonists for pain has been challenging — partly due to the redundancy of pain pathways and partly due to the dual physiological role of bradykinin in protective vasodilation.

Inflammation

In inflammatory contexts, bradykinin acts on multiple cell types to amplify the inflammatory cascade:

• •Endothelial cells: Increased permeability, upregulation of adhesion molecules (E-selectin, VCAM-1)
• •Mast cells: Histamine release via B2R (amplifying the histaminergic arm of inflammation)
• •Macrophages and fibroblasts: Cytokine production (IL-6, IL-8) and arachidonic acid metabolite synthesis
• •Sensory nerve endings: Neuropeptide release (Substance P, CGRP) via axon reflex, contributing to neurogenic inflammation

The interplay between kinin B2R (acute) and B1R (chronic, inflammation-induced) creates a self-amplifying loop: initial tissue injury activates B2R → generates pro-inflammatory cytokines → upregulates B1R → sustains chronic inflammatory tone via des-Arg⁹-bradykinin.

---

Bradykinin and the COVID-19 Bradykinin Storm Hypothesis

One of the most significant recent chapters in bradykinin research emerged from SARS-CoV-2 pathophysiology. A landmark 2020 computational analysis by Garvin et al. published in eLife (PMID: 32633718) analyzed single-cell RNA-seq data from COVID-19 bronchoalveolar lavage samples and identified profound dysregulation of the RAAS and kinin system — termed the "bradykinin storm."

Key molecular events in the proposed bradykinin storm:

• •SARS-CoV-2 binds ACE2 as its cellular receptor → ACE2 is downregulated/internalized
• •Loss of ACE2 reduces degradation of des-Arg⁹-bradykinin (the B1R agonist) → B1R-mediated signaling amplified
• •Simultaneously, viral infection upregulates multiple kallikrein enzymes and kininogens → increased bradykinin production
• •Both B1R and B2R are upregulated in infected tissue

This combination predicts massive accumulation of bradykinin and its metabolites in COVID-19 lung tissue, potentially explaining:

• •Pulmonary edema — bradykinin-driven capillary permeability increase
• •"Ground-glass" CT opacities — alveolar fluid accumulation
• •Hypotension and cardiovascular instability — systemic vasodilation
• •Neurological symptoms — B2R-mediated BBB permeability changes

The bradykinin storm hypothesis generated significant research attention, clinical trial activity with bradykinin pathway modulators, and broader interest in the KKS as a therapeutic target in acute respiratory and vascular pathology. A 2021 paper in Physiological Reports (PMID: 33687143) examined the debate directly, concluding that bradykinin and cytokine mechanisms likely operate in parallel with distinct clinical presentations.

---

Hereditary Angioedema: Bradykinin as the Master Mediator

Hereditary angioedema (HAE) is a rare but life-threatening condition characterized by episodic swelling of subcutaneous and submucosal tissues. The classical forms (HAE Type I and Type II) result from deficiency or dysfunction of C1 esterase inhibitor (C1-INH/SERPING1).

The pathophysiological chain:

1. C1-INH normally inhibits plasma kallikrein and FXIIa

2. Without functional C1-INH: FXIIa activates kallikrein without restraint

3. Kallikrein cleaves HK → generates excessive bradykinin

4. Bradykinin via B2R → massive endothelial vascular permeability increase → localized edema

The central role of bradykinin in HAE has been definitively validated by multiple therapeutic approvals:

1. Icatibant (Firazyr) — selective B2R antagonist peptide; subcutaneous injection halts acute attacks by blocking bradykinin-mediated permeability

2. Ecallantide (Kalbitor) — plasma kallikrein inhibitor; reduces BK generation upstream

3. C1-INH replacement therapies (Berinert, Cinryze, Haegarda) — address the root enzyme deficiency

4. Garadacimab (Andembry, approved 2025) — first-in-class FXIIa-targeted monoclonal antibody; Phase 3 VANGUARD trial showed 87% reduction in HAE attacks vs. placebo

5. Donidalorsen (Dawnzera, approved 2025) — first RNA-targeted prophylactic for HAE; reduces hepatic prekallikrein production; Phase 3 OASIS-HAE demonstrated 81% attack reduction

A 2024 discovery published in Blood identified a Kng1 point mutation (Met379Lys) in kininogens that dramatically increases kinin liberation by plasmin, expanding the genetic landscape of bradykinin-mediated angioedema beyond C1-INH deficiency and confirming the KKS as a rich source of novel disease mechanisms.

---

Bradykinin Analogs and Research Applications

For laboratory research, bradykinin and its analogs, antagonists, and metabolites are available as research-grade RUO peptides. These compounds are used in pharmacological characterization, receptor binding studies, cell signaling research, and in vivo models.

Key Research Agonists

Bradykinin (RPPGFSPFR)

The native nonapeptide; used to study B2R-mediated vasodilation, pain sensitization, and inflammatory cell activation. Standard positive control for B2R pharmacology assays. Short half-life requires careful experimental design — often combined with peptidase inhibitors (captopril, thiorphan) to prolong activity in biological fluids.

Des-Arg⁹-bradykinin

The carboxypeptidase-generated metabolite of bradykinin; selective B1R agonist. Used in models of chronic inflammatory pain, neuropathic pain, and B1R-specific pathway research. Valid B1R experiments require inflammatory induction protocols (e.g., IL-1β pretreatment) to upregulate B1R expression.

Kallidin (Lys-bradykinin)

The tissue kallikrein product; a decapeptide B2R agonist also processed to a B1R agonist after des-Arg¹⁰ cleavage. Useful for comparative studies of plasma vs. tissue kallikrein systems.

Key Research Antagonists

Icatibant (Hoe 140; D-Arg-[Hyp³,Thi⁵,D-Tic⁷,Oic⁸]-bradykinin)

The gold standard selective B2R antagonist. Metabolically stable (D-amino acids and non-natural amino acids prevent peptidase degradation), allowing prolonged in vivo effects. Used to definitively attribute biological effects to B2R activation. Validated in the HAE clinical setting (Firazyr).

Des-Arg⁹-[Leu⁸]-bradykinin

Classic selective B1R antagonist used in inflammatory pain models to assess the B1R contribution to nociception.

Experimental Considerations

• •Rapid enzymatic degradation: Add ACE inhibitor (captopril 10 μM) + NEP inhibitor (thiorphan 10 μM) to maintain bradykinin stability in biological fluids
• •B1R induction requirement: Valid B1R studies require pre-treatment with IL-1β or LPS to upregulate B1R expression in most cell types
• •Species differences: Rat, mouse, and human B1R/B2R have distinct pharmacological properties — species-appropriate tools are essential
• •TRPV1 co-expression: Bradykinin-induced nociceptor sensitization is most prominent in TRPV1-expressing (capsaicin-sensitive) neurons

---

Interactions with Other Peptide Research Systems

Renin-Angiotensin System

The KKS and RAAS share enzymatic machinery (ACE, ACE2) with opposing physiological roles. The counter-regulatory RAAS peptide Angiotensin-(1-7) acts through the Mas receptor to produce vasodilation and anti-inflammatory effects that parallel bradykinin''s cardiovascular protective actions. Both systems are disrupted in COVID-19 ACE2 pathophysiology, making their interaction a key research topic.

Neuropeptide Pain Systems

The nociceptive role of bradykinin intersects with Substance P and the tachykinin family and CGRP in neurogenic inflammation. Endogenous opioids including beta-endorphin provide counterbalancing antinociception. The net pain experience in inflammatory models reflects the balance of these pro- and anti-nociceptive peptide systems.

Natriuretic Peptide System

The natriuretic peptides (ANP, BNP, CNP) share the vasodilatory and natriuretic roles of bradykinin. Neprilysin — which degrades both natriuretic peptides and bradykinin — is pharmacologically targeted by sacubitril (in sacubitril/valsartan for heart failure), creating an intersection of these peptide systems in cardiovascular drug development.

---

Active Research Fronts (2026)

1. Structural pharmacology: Cryo-EM structures of B1R and B2R enable structure-based design of next-generation non-peptide antagonists for chronic inflammatory pain — a major unmet need

2. B1R as chronic pain target: The inducible, non-desensitizing nature of B1R makes it attractive for neuropathic and inflammatory pain drug development

3. HAE genetics expansion: Novel gain-of-function mutations (FXIIa, plasminogen, kininogens) causing non-C1-INH HAE continue to emerge

4. Long COVID: Persistent vascular and neurological symptoms in post-acute SARS-CoV-2 infection have reinvigorated interest in chronic KKS dysregulation

5. KKS drug pipeline: A 2024 review (DOI: 10.1186/s12967-024-05216-5) identified 68 drugs targeting the KKS — 10 approved, 25 in clinical development, 33 in preclinical development

---

Research Compound Summary

---

Summary

Bradykinin occupies a uniquely central position in vascular biology, inflammatory pharmacology, and pain research. As the key effector of the kallikrein-kinin system, it bridges the coagulation cascade, the RAAS, prostaglandin signaling, neuropeptide pathways, and the nociceptive nervous system. The 2025 approvals of garadacimab (Andembry) and donidalorsen (Dawnzera) — both targeting upstream components of the bradykinin generation cascade — confirm the ongoing translational relevance of kinin biology and validate decades of laboratory work on this 9-amino-acid peptide.

---

Key References

• •Garvin MR et al. "A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm." eLife 2020. PMID 32633718
• •Karamyan VT. "Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?" Physiological Reports 2021. PMID 33687143
• •de Oliveira SJ et al. "Bradykinin receptor expression and bradykinin-mediated sensitization of human sensory neurons." PAIN 2024. PMC10081334
• •Molecular basis for kinin selectivity and activation of the human bradykinin receptors. Nature Structural & Molecular Biology 2021. DOI 10.1038/s41594-021-00645-y
• •Veronez CL et al. "Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system." J Translational Medicine 2024. DOI 10.1186/s12967-024-05216-5
• •Whalley ET et al. "The kinin system — bradykinin: biological effects and clinical implications." PMC2658795

---

This article is for research and educational purposes only. Bradykinin and related kinin peptides are Research Use Only (RUO) compounds intended for in vitro laboratory investigation. They are not approved for human or veterinary therapeutic use, and this content does not constitute medical advice.